OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

Charlotte Primard,Elodie Monchâtre-Leroy,Judith Del Campo,Séverine Valsesia,Elsa Nikly,Marion Chevandier,Franck Boué,Alexandre Servat,Marine Wasniewski,Evelyne Picard-Meyer,Thomas Courant,Nicolas Collin,Francisco J. Salguero,Alexandre Le Vert,Delphine Guyon-Gellin,Florence Nicolas
DOI: https://doi.org/10.3389/fimmu.2023.1188605
IF: 7.3
2023-06-19
Frontiers in Immunology
Abstract:Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM ® , a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.
immunology
What problem does this paper attempt to address?